Beyhan Zaim, a member of the Healthcare and Pharmaceutical Management Advisory Board at Columbia Business School, has joined Novo Nordisk as Senior Vice President of Commercial Business Development (CBD). In this role, Beyhan will be responsible for identifying and executing partnerships and acquisitions which leverage Novo Nordisk’s unique capabilities. Beyhan will also be responsible for evolving Novo Nordisk’s commercial business model, strengthening Novo Nordisk’s digital health initiatives, patient support programs and multichannel patient engagements. She also oversees the corporate strategy function, new product planning and forecasting, commercial device strategy and the CSCA hub in Bangalore, India.
Beyhan joins Novo Nordisk with more than 20 years of experience as a commercial leader at Pfizer Inc., where she has held senior roles across a range of functions, therapeutic areas and geographies. Specific highlights include experience in leading large scale global M&A integrations (e.g. Warner Lambert acquisition), partnering and business development evaluations. Throughout her career Beyhan has established and/or led global alliances with Pfizer co-development/co-promote partners such as Boehringer-Ingelheim, Janssen, Medivation. She has overseen global marketing and launches of iconic brands such as Spiriva (respiratory), Lyrica (neuropathic pain), and Eliquis (cardiovascular) and led corporate strategy development for therapy areas such as GI/Hepatology (including NASH), cardiovascular/metabolic (including obesity and diabetes), pain, neuroscience (including AD) and respiratory. Additionally, Beyhan has deep experience of managing businesses in emerging markets with international assignments based in Hong Kong as Business Development Director, Asia and Country Manager, Pfizer Thailand, based in Bangkok.
Beyhan earned her MBA from Columbia Business School and Bachelor of Science degree from the Rutgers College of Pharmacy.